Abstract
Delivery to the brain is a challenging task due to its protection by the blood-brain barrier (BBB). Lipids and fatty acids are reported to affect the permeability of the BBB, although this has not been reported following oral administration. Cannabidiol (CBD) has high therapeutic potential in the brain, therefore, tis work investigated CBD delivery to anatomical brain regions following oral administration in lipid-based and lipid-free vehicles. All formulations resulted in a short brain Tmax (1 h) and brain-plasma ratios ≥3.5, with retention up to 18 h post administration. The highest CBD delivery was observed in the olfactory bulb and striatum, and the medulla pons and cerebellum the lowest. The lipid-free vehicle led to the highest levels of CBD in the whole brain. However, when each anatomical region was assessed individually, the long chain triglyceride-rich rapeseed oil formulation commonly showed optimal performance. The medium chain triglyceride-rich coconut oil formulation did not result in the highest CBD concentration in any brain region. Overall, differences in CBD delivery to the whole brain and various brain regions were observed following administration in different formulations, indicating that the oral formulation selection may be important for optimal delivery to specific regions of the brain.
Keywords: Blood-brain barrier, Brain regions, Cannabidiol, Lipid-based drug delivery, Oral
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Development and pharmacokinetic evaluation of a self-nanoemulsifying drug delivery system for the oral delivery of cannabidiol.Eur J Pharm Sci. 2022 Jan 1;168:106058. doi: 10.1016/j.ejps.2021.106058. Epub 2021 Nov 8.PMID: 34763088
-
Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers.Eur J Pharm Biopharm. 2020 Sep;154:108-115. doi: 10.1016/j.ejpb.2020.06.021. Epub 2020 Jul 4.PMID: 32634571 Clinical Trial.
-
Inclusion of Medium-Chain Triglyceride in Lipid-Based Formulation of Cannabidiol Facilitates Micellar Solubilization In Vitro, but In Vivo Performance Remains Superior with Pure Sesame Oil Vehicle.Pharmaceutics. 2021 Aug 27;13(9):1349. doi: 10.3390/pharmaceutics13091349.PMID: 34575426 Free PMC article.
-
Is oral lipid-based delivery for drug targeting to the brain feasible?Eur J Pharm Biopharm. 2022 Mar;172:112-122. doi: 10.1016/j.ejpb.2022.02.004. Epub 2022 Feb 8.PMID: 35149190 Review.
-
Cannabinoids, Blood-Brain Barrier, and Brain Disposition.Pharmaceutics. 2020 Mar 15;12(3):265. doi: 10.3390/pharmaceutics12030265.PMID: 32183416 Free PMC article. Review.
LinkOut – more resources
-
Full Text Sources